Literature DB >> 10325668

Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil).

J Devlin1, K Wagstaff, V Arthur, P Emery.   

Abstract

OBJECTIVE: Methotrexate (MTX) is an increasingly popular anti-rheumatic drug with its usefulness limited by toxicity, most commonly gastrointestinal (GI). The aim of the study was to study the effectiveness of the 5-HT3 receptor antagonist granisetron (GR) in the therapy of MTX-induced nausea.
METHODS: A single-blind 8 week pilot study with random allocation to either GR 1 mg or prochlorperazine (Stemetil; PCh) 10 mg was undertaken in 13 patients who were taking or had taken MTX for either rheumatoid arthritis (10) or psoriatic arthritis (3).
RESULTS: One in six patients treated with PCh completed the 8 week study compared to 7/7 treated with GR. After switching of symptomatic patients, 11 completed the study on GR and median improvement was by two grades (P < 0.001) with a significantly better visual analogue scale score for patient satisfaction compared to PCh.
CONCLUSION: Treatment with GR may be useful in establishing and maintaining some patients on MTX where GI toxicity would have precluded such therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10325668     DOI: 10.1093/rheumatology/38.3.280

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  3 in total

Review 1.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

2.  Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX.

Authors:  S L Hider; W Thomson; L F Mack; D J Armstrong; M Shadforth; I N Bruce
Journal:  Rheumatology (Oxford)       Date:  2008-06-06       Impact factor: 7.580

Review 3.  Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.

Authors:  Paul Emery; Anthony Sebba; Tom W J Huizinga
Journal:  Ann Rheum Dis       Date:  2013-08-05       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.